国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2009年
21期
68-70
,共3页
慢性心力衰竭%卡托普利%美托洛尔
慢性心力衰竭%卡託普利%美託洛爾
만성심력쇠갈%잡탁보리%미탁락이
Chronic heart failure%Captopril%Metoprolol
目的 评价在常规强心、利尿治疗基础上,卡托普利与美托洛尔治疗慢性充血性心力衰竭的疗效.方法 选择慢性充血性心力衰竭病人90例,随机分为观察组与对照组,观察组(45例)在常规治疗的基础上,加用卡托普利与美托洛尔,观察8周.对照组(45例)为常规治疗组,常规给予地予高辛和利尿剂治疗.结果 3年间,治疗组与对照组有效率分别为86.67%和66.67%,差异具有统计学意义(P<0.05),治疗组与对照组左审收缩末期内径、左室舒张末期内径、左室射血分数均有显著差别,P<0.01,治疗组比对照组疗效显著.结论 卡托普利联合美托洛尔治疗慢性充血性心力衰竭临床疗效更好.
目的 評價在常規彊心、利尿治療基礎上,卡託普利與美託洛爾治療慢性充血性心力衰竭的療效.方法 選擇慢性充血性心力衰竭病人90例,隨機分為觀察組與對照組,觀察組(45例)在常規治療的基礎上,加用卡託普利與美託洛爾,觀察8週.對照組(45例)為常規治療組,常規給予地予高辛和利尿劑治療.結果 3年間,治療組與對照組有效率分彆為86.67%和66.67%,差異具有統計學意義(P<0.05),治療組與對照組左審收縮末期內徑、左室舒張末期內徑、左室射血分數均有顯著差彆,P<0.01,治療組比對照組療效顯著.結論 卡託普利聯閤美託洛爾治療慢性充血性心力衰竭臨床療效更好.
목적 평개재상규강심、이뇨치료기출상,잡탁보리여미탁락이치료만성충혈성심력쇠갈적료효.방법 선택만성충혈성심력쇠갈병인90례,수궤분위관찰조여대조조,관찰조(45례)재상규치료적기출상,가용잡탁보리여미탁락이,관찰8주.대조조(45례)위상규치료조,상규급여지여고신화이뇨제치료.결과 3년간,치료조여대조조유효솔분별위86.67%화66.67%,차이구유통계학의의(P<0.05),치료조여대조조좌심수축말기내경、좌실서장말기내경、좌실사혈분수균유현저차별,P<0.01,치료조비대조조료효현저.결론 잡탁보리연합미탁락이치료만성충혈성심력쇠갈림상료효경호.
Objective To evaluate the conventional cardiac,diuretic therapy,captopril and metoprolol in the treatment of chronic congestive heart failure.Methods 90 cases of patients with chronic congestive heart failure were randomly divided into two groups:the control group and the observation group(with 45 cases each).on the basis of conventional treatment,it had the addition of captopril and metoprolol.it was observed for 8 weeks.The control group(45 oases)has the conventional treatment with digoxin and diuretic.Results With 3 years,the treatment group and control group effective rate was 86.67% percent and 66.67% percent respectively.Treatment group and control group left ventricular end systolic diameter,left ventricular end diastolic diameter,left ventricular ejection fraction have significant difference,P<0.01,there were significant effect in the treatment group compared with the control group.Conclusions The treatment of captopril combined with metoprolol for the chronic congestive heart failure can improve the clinical efficacy.